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Site-specific mutations have been made in the influenza hemagglutinin (HA) receptor binding site to assess the contribution of
individual amino acid residues to receptor recognition. Screening of mutant HAs, expressed using recombinant vaccinia virus-
infected cells, for their abilities to bind human erythrocytes indicated that substitutions involving conserved residues Y98F, H183F,
and L194A severely restricted binding and that the substitution W153A prevented cell surface expression of HA. Mutation of
residues E190 and S228 that are in positions to form hydrogen bonds with the 9-OH of sialic acid appeared to increase erythrocyte
binding slightly, as did the substitution G225R. Substitutions of other residues that are directly or indirectly involved in receptor
binding, S136T, S136A, Y195F, G225D, and L226P, had intermediate effects on binding between these two extremes. Estimates of
changes in receptor binding specificity based on inhibition of binding to erythrocytes by nonimmune horse sera indicated that
mutants G225R and L226P, unlike wild-type HA, were not inhibited; Y195F and G225D mutants were, like wild type, inhibited; and
erythrocyte binding by mutants S136A, S136T, E190A, and S228G was only partially inhibited. Viruses containing mutant HAs Y98F,
S136T, G225D, and S228G that cover the range of erythrocyte binding properties observed were also constructed by transfection.
All four transfectant viruses replicated in MDCK cells and embryonated hens’ eggs as efficiently as wild-type X-31 virus, although
the Y98F mutant virus was unable to agglutinate erythrocytes. Mutant MDCK cells that have reduced levels of cell surface sialic
acids were susceptible to infection by S136T, G225D, and S228G transfectant viruses and by wild type but not by the Y98F
transfectant virus. © 1998 Academic Press
INTRODUCTION
Sialic acids of cell surface glycoproteins and glycolip-
ids are receptors for influenza viruses (reviewed in
Gottschalk, 1959); the virus components that recognize
them are the hemagglutinin (HA) glycoproteins of the
virus membrane (reviewed in Wiley and Skehel, 1987).
The sites at which the receptors are bound are at the
virus membrane distal tip of each subunit of the HA
trimer. This region was recognized in the initial X-ray
structure analysis of HA (Wilson et al., 1981) as a pocket
of conserved residues with the potential, because of its
location, to be involved in receptor recognition. Its iden-
tity as the receptor binding site was deduced from the
molecular locations of variant residues in mutant HAs
which displayed different binding properties (Rogers et
al., 1983) and this was confirmed by X-ray structures of
HA–receptor analogue complexes (Fig. 1; Weis et al.,
1988; Sauter et al., 1992; Watowich et al., 1994; Eisen et
al., 1997). These results indicate that conserved residues
tryptophan 153, tyrosine 195, histidine 183, and tyrosine
98 interact in a hydrogen-bonded network to form the
base of the site; glutamic acid 190 and leucine 194 are
generally conserved residues in a short a-helix that
forms its membrane distal edge; and conserved serine
136 is on its lower edge. Analysis of such HA–receptor
analogue complex structures together with studies of
receptor analogue binding in solution (Sauter et al., 1989)
demonstrate the orientation of bound sialic acid in the
site, the interactions it makes with the protein, and the
importance for binding of its different substituents. Sialic
acid is bound with one side of the pyranose ring facing
toward the base of the site. The axial carboxylate, the
acetamido nitrogen, and the 8- and 9-hydroxyls face into
the site and hydrogen bond with conserved side chain or
main chain polar atoms. Thus, conserved serine 136
forms a hydrogen bond with the carboxylate which is
also hydrogen bonded to the amide of peptide bond 137;
histidine 183 and glutamic acid 190 hydrogen bond with
the 9-hydroxyl group and tyrosine 98 with the 8-hydroxyl.
The 5-acetamido nitrogen forms a hydrogen bond with
the carbonyl of peptide bond 135 and the methyl group of
this substituent is in van der Waals contact with the
six-membered ring of tryptophan 153. The 7-hydroxyl and
acetamido carbonyl hydrogen bond to each other and
form van der Waals contacts with leucine 194. By com-
parison the 4-hydroxyl projects out of the site and ap-
pears not to participate in binding.
Differences in receptor recognition specificity that
have been reported include distinction between the a2,3
and a2,6 linkages that terminal sialic acids make with
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penultimate residues in carbohydrate side chains (Rog-
ers et al., 1983; Connor et al., 1994). None of the atoms
involved in the linkages interacts directly with amino acid
residues in the site but substitutions of leucine 226 in
particular, on the left edge of the site, have been asso-
ciated with changes in linkage recognition specificity
(Rogers et al., 1983). The orientations of the carbohydrate
side chains as they extend out of the site are determined
by these glycosidic linkages and are quite distinct. Pen-
tasaccharides containing the a2,3-linked chain exit the
site toward the trimeric interface near glutamic acid 190;
a2,6-linked chains on the other hand, as a result of their
folded conformation, exit toward the opposite end of the
short membrane distal a-helix, near residue 194 (Eisen et
al., 1997). The binding affinities of these pentasacchar-
ides are found to be similar to that of a-methylsialic acid
(Sauter et al., 1989; Weinhold and Knowles, 1992;
Charych et al., 1993), which is consistent with the obser-
vation that in the analogues studied only the terminal
sialic acid makes contact with the HA surface.
In the studies reported here we have examined the
importance of the contributions of individual residues in
the site for binding and specificity. We have specifically
substituted all conserved residues in the site and a
number on the left edge of the site that have been
implicated in binding specificity and we have expressed
the mutant HAs in recombinant vaccinia virus-infected
cells and in influenza viruses constructed by reverse
genetics. Our observations highlight the importance of
tryptophan 153 for the structure of HA in this region,
demonstrate the special importance for binding of ty-
rosine 98, histidine 183, and leucine 194, and confirm the
cooperative nature of HA–receptor interactions involved
in virus infection.
RESULTS
The amino acid substitutions that we have introduced
into the sialic acid binding site replace individually the
conserved residues W153, Y195, H183, and Y98 that are
linked by hydrogen bonds and positioned centrally in the
base of the site; S 136, a conserved hydroxyl amino acid
on the lower edge of the site; E 190 and L 194, conserved
residues that are components of the short a-helix form-
ing the virus membrane distal edge of the site; and
residues G 225, L 226, and S 228 on the left edge of the
site nearest the trimeric interface (Fig. 1). The mutations
involve residues of similar size with different functional-
ity, Y98F, S136A, H183F, Y195F; exchanges for alanine,
E190A, L194A, W153A; or substitutions that have oc-
curred in the HAs of previously described natural iso-
lates or laboratory-selected mutants, S136T, G225D,
G225R, S228G, and L226P. These substitutions, together
with the interactions that the residues make and the
degree of their conservation, are listed in Table 1.
Studies using recombinant vaccinia
virus-expressed HA mutants
Surface expression and antigenicity of mutant HAs
(a) Accessibility to proteolytic processing. Recombi-
nant vaccinia virus-infected cells express the HA on the
cell surface in the uncleaved precursor form, HA0. In
order to activate the fusion potential of HA, expressing
cells are treated with a protease such as trypsin to
cleave HA0 into HA1 and HA2. The accessibility of ex-
pressed HA0 to trypsin provides an assay for cell surface
transport. CV1 cell monolayers were infected in parallel
with different recombinant vaccinia viruses and cell
monolayers expressing wild-type (wt) and mutant HAs
were incubated in the presence or the absence of tryp-
sin. Immunoblot analysis of the cell lysates with poly-
clonal serum against HA revealed that all HAs with the
exception of W153A were cleaved into HA1 and HA2 (Fig.
2), indicating that this mutant may not have been trans-
ported to the cell surface but that all others were. It is
possible that this protein does not fold correctly and is
degraded intracellularly.
(b) Antibody recognition. The mutant HAs were also
analyzed by ELISA using a panel of five monoclonal
antibodies which bind to structurally distinct antigenic
regions of wt HA; HC3, HC31, HC68, HC100, and HC263
select for neutralization-resistant mutants with changes
at HA1 residues 146, 198, 193, 63, and 158, respectively
(Daniels et al., 1983). Confluent HeLa cell monolayers
were infected with recombinant vaccinia viruses and at
15 h postinfection antibody reactivities with cell surface
HAs were determined (Table 2). The experiment was
also done using HA-expressing cells either untreated or
treated with trypsin to cleave HA0 into HA1 and HA2 and
the antibodies reacted equally well with HA0 and cleaved
HAs in each case (not shown). The mutant W153A failed
to react with any of the monoclonal antibodies, support-
ing the evidence from the trypsin cleavage experiments
that this mutant HA is not transported to the cell surface.
Other mutants, H183F, and Y195F had somewhat lower
reactivities to all monoclonal antibodies, suggesting a
reduced level of cell surface expression rather than an
effect of these mutations on the antigenic structure of
any specific region of the molecule. Two examples were
observed in which the mutation resulted in loss of anti-
body reactivity; monoclonal antibody HC68 failed to react
with mutants L226P and S136A. This antibody has been
shown previously to select neutralization-resistant mu-
tants with a substitution at residue 193 of HA1 (Daniels et
al., 1983), which is in the short a-helix at the membrane
distal edge of the receptor binding site, about 15 Å from
residues 226 and 136. These residues may, therefore,
also be components of the antibody binding site.
(c) Membrane fusion activities of mutant HAs. Follow-
ing trypsin treatment and incubation at pH 5.0, none of
the cell surface-expressed mutants reacted with HC31
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and HC68, the two antibodies known to react with the
native but not the low-pH conformation of HA. This sug-
gests that all surface-expressed HAs are capable of
going through the characteristic acid-induced conforma-
tional changes required for membrane fusion activity.
The capacities of wild-type and mutant HAs to mediate
membrane fusion and the pH at which fusion takes place
were assayed by recording polykaryon formation by HA-
expressing cells. Following infection with recombinant
vaccinia viruses, HA-expressing BHK cell monolayers
were trypsin-treated and incubated at the pH indicated
(Fig. 3). Cells were then neutralized and observed for
polykaryon formation by microscopy. All mutants except
W153A, which is not expressed on the cell surface,
clearly mediate fusion and all had activity at the same pH
as wild-type HA, between pH 5.3 and 5.5, with the ex-
ception of the mutant L226P, which displayed fusion
activity between pH 5.7 and 5.9. The elevated pH of
fusion for L226P HA correlates with the elevated pH of
fusion reported previously for a double mutant contain-
ing this amino acid substitution (Daniels et al., 1987). No
polykaryon formation was observed following low-pH
FIG. 1. Schematic diagram of the receptor binding site of a HA–receptor analogue complex, showing the positions of the residues changed in the
mutants described and hydrogen bonds that in wt HA they form with bound sialic acid (bold dotted lines). HA is shown in light blue and sialic acid
in green. Oxygen atoms are represented in red and nitrogen atoms in purple.
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incubation of cells infected with nonrecombinant vac-
cinia viruses or when the HA-expressing cells were not
treated with trypsin to cleave HA0.
The results of these three different assays of HA ex-
pression and function indicate that with the exception of
W153A HA the mutants used in this study are expressed
on the cell surface, are folded correctly, and are func-
tional with respect to membrane fusion activity.
Receptor binding activity of mutant HAs
The receptor binding activity of mutant HAs was as-
sayed by binding human erythrocytes loaded with horse-
radish peroxidase (HRP) to HA-expressing HeLa cell
monolayers. Recombinant vaccinia virus-infected HeLa
cell monolayers expressing the wild-type and mutant
HAs were treated with neuraminidase and then with
trypsin, to cleave HA0 into HA1 and HA2, and incubated
with HRP-loaded erythrocytes for 40 min at 37°C. Cells
were washed several times to remove unbound erythro-
cytes and binding was quantitated by assaying for the
level of HRP activity due to erythrocytes which were still
bound. The level of expression of the HAs was assessed
in parallel by ELISA. The results for binding activity were
corrected for level of HA expression and are presented in
Table 3 as percentages of the values obtained for wild-
type HA. As negative controls either vaccinia-infected
cells not expressing HA or erythrocytes which had been
pretreated with neuraminidase to remove receptors for
HA were used. Using these controls there was no bind-
ing of erythrocytes to vaccinia-infected cell monolayers.
For three of the mutants, E190A, G225R, and S228G,
binding activity was slightly higher than that of wild-type
HA. A number of mutants displayed only partial binding
activity and for three of the mutants, Y98F, H183F, and
L194A, binding activity was almost completely abolished.
Comparative binding studies of wild-type HA, L194A,
E190A, and Y98F mutants were also done using surface
plasmon resonance assays (Takemoto et al., 1996). The
results were similar to those reported here except that
TABLE 1
Amino Acid Substitutions, Contacts, and Degrees of Conservation of Residues
Substitution Contacts in binding site
Conservation
H3 subtype All subtypes
Y98F Y98 OH H1 bond to NeuAc O8 and H183 NE Y Y
S136 T/A S136 OH H1 bond to NeuAc O1 S S/T
W153A W153 N H1 bond to Y195 OH; van der Waals contact with NeuAc C7 and acetamido methyl W W
H183F H183 NE2 H1 bond to NeuAc O9 and Y98 OH; NE1 H1 bond to Y195 OH. H H
E190A E190 OE H1 bond to NeuAc O9 E/D/V D/E/N/V
L194A van der Waals contact with NeuAc C7 and acetamido O L/I L/I
Y195F H1 bonds to W153 N and H183 NE Y Y
G225D/R van der Waals contact with A138 Cb G G/D/N
L226P van der Waals contact with NeuAc C8 and A138 Cb L/Q/V/I L/Q/V/I
S228G S228 OH H1 bond to NeuAc O9 S G/S
FIG. 2. Immunoblot analysis of a reducing polyacrylamide gel of
lysates from monolayers of vaccinia-infected wt or mutant HA-express-
ing CV 1 cells following incubation with (1) or without (2) trypsin. (A)
G225D, (B) G225R, (C) W153A, (D) E190A, (E) S136A, (F) S136T, (G)
L226P, (H) H183F, (I) Y195F, (J) WT, (K) S228G, (L) L194A, (M) Y98F.
TABLE 2
Monoclonal Antibody Reactivity to HA Receptor Mutants
HC3 HC31 HC68 HC100 HC263
WT .606 .543 1.085 .403 .377
G225D .694 .565 .891 .355 .367
G225R .629 .557 .935 .431 .417
W153A .026 .013 .029 .033 .020
L226P .938 .840 .027 .463 .399
E190A .709 .487 1.015 .378 .355
H183F .402 .228 .583 .318 .274
Y98F .977 1.174 1.466 .591 .543
S228G .721 .641 1.178 .392 .374
L194A .664 .368 .782 .369 .320
Y195F .298 .186 .526 .250 .236
S136A .731 .745 .098 .458 .418
S136T .860 .849 1.149 .468 .457
Note. Values represent OD450 nm ELISA readings.
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lower binding activity was recorded for mutant E190A
(Takemoto, 1997).
We also assayed the mutant HAs for their ability to
bind erythrocytes in the presence of horse serum, which
functions as a potent binding inhibitor of HAs such as
wild-type X-31 HA that recognize sialic acid in a2,6 link-
age (Pritchett and Paulson, 1989). The data in Table 4
show that Y195F and G225D HAs were inhibited to the
same extent as wild-type HA. The other mutant HAs
displayed a range of inhibition, with mutant L226P being
the most resistant to inhibition. This is consistent with
the observation that growth of X-31 virus in the presence
of horse serum selects for mutations at residue 226
(Rogers et al., 1983). These results indicate that mutants
S136A, S136T, E190A, G225R, L226P, and S228G are
more resistant than wt HA to inhibition by nonimmune
horse sera, and this may reflect their abilities to bind
sialic acid in a2,3 linkage. To assess the ability of the
mutants to recognize sialic acid containing 5-N-glycolyl
substituents we also determined their binding activities
using horse erythrocytes. Like wild-type X-31, none of the
mutants bound these erythrocytes.
Studies using transfectant viruses
Generation of receptor-site mutant transfectant viruses
The above results demonstrate that substitution of
conserved residues in the receptor binding site can
FIG. 3. Polykaryon formation by HA-expressing BHK cells following incubation at the indicated pH. The subscript refers to the fact that these
residues are all in the HA1 subunit.
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affect the ability of HA to bind to human erythrocytes. To
determine the significance of this binding for virus infec-
tivity, mutant transfectant viruses were generated.
cDNAs corresponding to mutant HAs with poor (Y98F),
intermediate (S136T and G225D), and strong (S228G)
erythrocyte binding activities were subcloned into the
reverse genetics vector pT3 X-31, and mutant and wild-
type transfectant viruses were constructed as described
previously (Enami and Palese, 1991).
Infectivity of transfectant viruses
All transfectant viruses replicated in MDCK cells and
embryonated chicken eggs yielding virus at titers of
approximately 107 plaque-forming units (PFU)/ml. Assays
of the ability of the MDCK-grown viruses to agglutinate
human and turkey erythrocytes indicated that all except
Y98F were able to efficiently agglutinate erythrocytes
from both species (Table 5). Hemagglutination by Y98F
virus was detectable only when more dilute preparations
of erythrocytes were used. Similar results were obtained
with egg-grown viruses.
Infectivity of transfectant viruses in cells with low
sialic acid content
All four receptor-site mutant transfectant viruses in-
cluding Y98F, which was unable to agglutinate erythro-
cytes, were able to infect MDCK cells and eggs with
efficiencies comparable to those of wild type. One ex-
planation of this observation is that sialic acid-containing
receptors are abundant in these two systems (Ito et al.,
1997) and allow a sufficient number of HA–sialic acid
interactions to occur for effective virus attachment, even
for mutant viruses with low binding activity. To examine
this possibility a mutant ricin-resistant MDCK cell line
(MDCK RCAr) with reduced levels of sialic acid-contain-
ing glycoconjugates on the cell surface, was also used
for infectivity studies. These cells have a 70 to 75%
reduction in cell surface sialic acid (Bra¨ndli et al., 1988)
but retain the typical characteristics of polarized epithe-
lial cells and have been reported to support VSV and
influenza infections, although virus yields were slightly
reduced (Green et al., 1981). The transfectant viruses
were adsorbed in parallel on monolayers of mutant and
wild-type MDCK cells and their infectivity was deter-
mined by plaque assay (Fig. 4). Although infectivity and
plaque size are slightly reduced for wild type, S228G, and
S136T viruses, the effects are much more dramatic with
the Y98F virus. Figure 5 shows monolayers of both cell
types overlaid with five dilutions of wild-type HA and
Y98F virus stocks of approximately equal infectivity titer
TABLE 3
Human Erythrocyte Binding (% of Wild Type)
HA
Experiment
Average1 2 3 4
WT 100 100 100 100 100
Y98F 5 7 5 3 5
S136A 25 30 27 38 30
S136T 31 32 46 70 45
H183F — — 16 7 12
E190A 106 110 138 144 125
L194A 4 2 4 2 3
Y195F 34 56 29 26 36
G225D 38 48 46 78 53
G225R 98 131 139 175 136
L226P 31 33 37 63 42
S228G — — 93 130 112
Note. All values are corrected for levels of HA expression.
TABLE 4
Percentage of Inhibition of Human RBC Binding by Horse Serum
HA 1% Serum 10% Serum
WT 83 99
Y98Fa — —
S136A 45 74
S136T 16 76
H183Fa — —
E190A 33 87
E194Aa — —
Y195F 79 94
G225D 82 96
G225R 9 57
L226P 5 30
S228G 26 78
a Binding of these mutants was too low in the absence of serum to
measure a level of inhibition.
TABLE 5
Hemagglutination Activities of the Mutant Receptor-Site Virusesa
Virus
Titerb
[(PFU/ml (107)]
Erythrocytesc
Human Turkey
WT 2 256 256
Y98F 1 ,2 ,2
S136T 0.7 128 128
G225D 0.7 1024 512
S228G 1 ND 512
Percentage of Turkey erythrocytes
Virus 0.3 0.5 0.7
WT 1024 512 256
Y98F 64 16 ,2
Note. ND, Not determined.
a HA units per 100 ml of virus supernatant.
b Determined by plaque assay in MDCK cells.
c 0.7% concentration of erythrocytes used.
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on wild-type MDCK cells and clearly demonstrates the
restriction of infectivity and growth of Y98F virus on the
sialic acid-depleted cell line. These results illustrate that
infection of cells by influenza viruses, which is assumed
to involve multiple HA–sialic acid interactions, is influ-
enced by the abundance of receptors on the cell surface
when the affinity of the HA for sialic acid is reduced.
DISCUSSION
Our analyses of the consequences for HA structure
and receptor binding properties of the site-specific mu-
tations we have introduced lead to three main conclu-
sions. First, all except one mutant HA were expressed at
the cell surface, reacted as native trimers with monoclo-
nal antibodies of known specificity, and were specifically
cleaved with trypsin into HA1 and HA2 to allow activation
at low pH of their fusion potentials. We concluded, there-
fore, that all except one of the mutants were expressed
as native, functional HAs. The exception, W153A, was
expressed at a low level but was not detected at the cell
surface. These observations are consistent with a struc-
tural role for this residue in the receptor binding site in
addition to a direct role in receptor binding due to its
proximity to the acetamido substituent of sialic acid (Sau-
ter et al., 1989). As a component of the hydrogen-bonded
network of residues in the base of the site W153 interacts
with Y195 and also forms part of an edge to face stack of
aromatic residues with phenylalanines 147 and 148. The
observation that mutant Y195F is able to bind to eryth-
rocytes indicates that the hydrogen bond formed be-
tween W153 and Y195 is not essential for either receptor
binding or for maintaining the structure of the site.
Second, on the basis of their abilities to bind erythro-
cytes the mutants can be divided into three groups:
(a) The mutant HAs Y98F, H183F, and L194A bound
only weakly to erythrocytes; binding by L194A was con-
sistently close to background. All three of these residues
are conserved in influenza A HAs; in influenza B residue
98 is phenylalanine (Krystal et al., 1983). Tyrosine 98
forms a hydrogen bond with histidine 183 and also ap-
pears to be the only residue in the site to interact with the
8-OH of sialic acid. Loss of either of these contacts may
be responsible for the decrease in binding activity. The
importance of the Y98–H183 interaction is also sug-
gested by the negative binding phenotype of H183F.
Although H183 forms a second hydrogen bond with the
FIG. 4. Plaque assays on MDCK and MDCK RCAr cell monolayers infected with transfectant viruses using two different dilutions of virus stocks
of approximately equal titer. The plates labeled 2 are 10-fold dilutions of the plates labeled 1.
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9-OH substituent of sialic acid, E190 and S228 also
interact with this substituent and may compensate for its
loss in the H183F mutant. In addition the reported un-
changed binding of 9-deoxysialic acid to HA suggests
that none of the hydrogen bonds to the 9-OH plays a
major role in receptor binding affinity (Kelm et al., 1992).
Together with W153 and L194, H183 is also involved in
forming a hydrophobic surface with which the acetamido
methyl group, C7, and C9 of sialic acid interact. The strict
conservation of all three residues would be consistent
with a major contribution of this surface to receptor
binding and changes in the structure of the site as a
result of the H183F substitution may indicate its impor-
tance.
(b) S136A, S136T, Y195F, G225D, and L226P demon-
strate intermediate levels of erythrocyte binding. S136T, a
natural variant in HAs of other subtypes, consistently
bound to a greater extent than S136A, supporting the role
of the conserved OH–amino acid in this position in form-
ing a hydrogen bond with the carboxylate at position 1 of
sialic acid. The peptide bond 137 amide proton also
interacts with the carboxylate and this may explain the
only partial abrogation of binding by the S136A mutation.
Tyrosine 195 is a component of the hydrogen-bonded
network of conserved residues that forms the base of the
binding site and therefore plays a role in positioning
these residues for their contacts with sialic acid, a role
which appears to be at least partially fulfilled in the
Y195F mutant. G225D is a natural variant in influenza H1
subtype HAs, although glycine 225 is conserved in all
other influenza A HAs. This residue does not contact
sialic acid but is part of a hydrophobic surface at the
lower left edge of the receptor binding site. The glycine
to aspartic acid substitution may influence the shape of
this surface and the positions of residues 136 and 137
which contribute to it and are also responsible for inter-
actions with the carboxylate of sialic acid.
The mutation L226P was previously reported to be one
of two substitutions, together with S193N, in a monoclo-
nal antibody-selected antigenic variant of X-31 (Daniels
et al., 1987). The selected variant was observed to dis-
play only transient hemagglutination and this is consis-
tent with the decreased binding to erythrocytes that we
recorded. Uniquely of the mutants analyzed here this HA
fused cellular membranes to form polykaryons at higher
pH than wild-type HA, pH 5.8 rather than pH 5.4, probably
due to an effect of the mutation on the stability of the
HA1–HA1 interface (Daniels et al., 1985, 1987). It is pos-
FIG. 5. Plaque assays of 10-fold dilutions of approximately equal titer stocks of wild-type and Y98F transfectant viruses on monolayers of MDCK
and MDCK RCAr cells.
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sible that a structural change in the receptor binding site
which this observation implies is responsible for the
reduced ability of this mutant to bind erythrocytes.
(c) The mutants E190A, G225R, and S228G appeared
to bind to erythrocytes slightly more efficiently than wild-
type HA. As noted above, substitutions at residue 225
may influence the positions on the lower edge of the site,
of residues 136 and 137 that hydrogen bond with the
sialic acid carboxylate. The increased binding by G225R
may be a consequence of a similar but opposite effect of
this mutation. Residue 190 is a conserved charged res-
idue in the majority of HAs of all subtypes sequenced. It
is in a position on the membrane distal edge of the site
to hydrogen bond with the 9-OH of sialic acid, but in
agreement with previous reports that HA has an un-
changed affinity for 9-deoxysialic acid, the E190–9-OH
interactions appear not to be essential for binding to
human erythrocytes. Residue 228 is serine or glycine in
all influenza A HAs. In X-31 HA S228 like E190 forms a
hydrogen bond with the 9-OH of sialic acid. It is therefore
not unexpected that the mutants S228G and E190A have
similar binding phenotypes and, again, this is consistent
with the unchanged binding of 9-deoxysialic acid (Kelm
et al., 1992).
Third, our estimates of changes in binding specificity
were based on the inhibition of HA binding to erythro-
cytes by nonimmune horse sera which are known to be
rich sources of sialic acids in a-2,6 linkage. For H3
subtype HAs results obtained with this assay have been
observed to correlate with estimates of binding specific-
ity derived from the use of cells derivatized with specific
sialyltransferases (Rogers et al., 1983). The extent of
binding to erythrocytes of the three mutants Y98F, H183F,
and L194A was too low to determine accurately the
inhibition of binding by horse serum. Of the other mu-
tants the specificities of Y195F and G225D were indis-
tinguishable from that of wild type but G225R and L226P
were clearly different, suggesting that they may prefer-
entially recognize sialic acid in a2,3 linkage. This con-
clusion is in agreement with previous observations of the
importance of residue 226 in influencing receptor bind-
ing specificity and with the effect of the L226P mutation
on specificity estimated using both horse sera inhibition
of hemagglutination by mutant virus and assays of virus
binding to specifically derivatized erythrocytes (Daniels
et al., 1987). Erythrocyte binding by the four remaining
mutant HAs, S136A, S136T, E190A, and S228G, was in-
hibited to intermediate levels between these two ex-
tremes of sensitivity and, again, mutant viruses with
similar characteristics have been observed before (Rog-
ers et al., 1983). The molecular basis of the differences
observed in receptor recognition specificity observed
now for numerous mutant HAs has not been extensively
explored. From structural studies of the L226Q mutant it
appears that the left edge of the site containing Q226
closes toward S136 on the lower edge so that Q226 and
S136 form a hydrogen bond. The position of Y98 is also
changed to fill the space occupied in wild-type HA by the
lower methyl group of leucine 226 and this change is
accompanied by the movement en bloc of the hydrogen
bonded residues 183, 195, and 153, with retention of their
interresidue spacings (Weis et al., 1988). Such small
changes in the structure of the site are presumed to
result in specificity differences even though none of the
atoms of the 2,3 or 2,6 linkages contacts directly the
different amino acid side chains of residue 226. The
mutations in the same region studied here, L226P and
G225R, cause the clearest differences in binding speci-
ficity and may result in similar structural rearrangements.
Equilibrium binding studies of wild-type X-31 and mutant
HAs to the a-methylglycoside of sialic acid by NMR spec-
troscopy indicate a dissociation constant of 2.8 mM and
experiments with a variety of a-linked sialoside receptor
analogues have given similar values (Sauter et al., 1989,
1992). Attachment of viruses to cells at the beginning of
infection is, therefore, assumed to involve a number of
HA–receptor interactions that cooperatively bind a virus
particle to the cell surface. Our experiments with viruses
constructed by reverse genetics to contain specific recep-
tor mutant HAs support this assumption. They indicate that
even viruses containing HAs with one of the lowest affini-
ties for erythrocyte receptors, Y98F, was capable of infect-
ing eggs and MDCK cells to produce yields of infectious
virus similar to that of wild-type X-31.
Further supportive evidence for the involvement of
several HAs in effective cell association is provided by
our experiments in which MDCK variant cells with less
abundant cell surface sialic acid were not susceptible to
infection by the weak binding mutant Y98F. These results
emphasize the importance of cell surface sialic acid for
influenza virus infection and also point to a balance that
appears to exist between effective HA affinity, multiple
HA–cell surface interactions, and infectivity. However, it
seems that given a sufficient cell surface density of sialic
acids, irrespective of linkage recognition specificity, in-
fluenza viruses will be capable of infecting cells.
MATERIALS AND METHODS
Mutagenesis, HA expression, and reverse genetics
The site-specific HA receptor mutations were gener-
ated either by the method of Kunkel et al. (1987) or by
polymerase chain reaction (PCR) with mutant primers.
The system developed by Blasco and Moss (1995) was
used to make recombinant vaccinia viruses for HA ex-
pression. The vaccinia virus vRB 12 and expression vec-
tor pRB 21 used in this system were kindly provided by
Dr. Bernard Moss. These viruses were generated and
propagated in CV1 cells grown in Dulbecco’s modified
Eagle’s medium supplemented with 5% fetal calf serum.
Transfectant influenza viruses were generated essen-
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tially as described by Enami and Palese (1991) using
WSN virus (A/WSN/33, H1N1) as helper virus and the
reverse genetics vector pT3 X-31. This plasmid contains
the cDNA of the HA gene of A/Aichi/2/68 (H3N2) virus
with a bacteriophage T3 promoter and a BsaI site posi-
tioned such that linearization of the vector followed by in
vitro transcription yields vRNA sense transcripts of the
HA gene with exact 39 and 59 noncoding terminal se-
quences. The infection/transfection step was done in
MDBK cells and transfectant viruses were selected for
growth in MDCK cells in the presence of anti-WSN rabbit
serum.
Surface expression and membrane fusion assays
Assays for HA cell surface expression by trypsin
cleavability were done using recombinant vaccinia virus-
expressed HA on CV1 cells as described previously
(Steinhauer et al., 1995). Antibody reactivity was analyzed
on recombinant vaccinia virus-infected HA-expressing
HeLa cells by ELISA (Steinhauer et al., 1991b) using a
panel of monoclonal antibodies to different structural
regions of the HA and a protein A-HRP conjugate. The
pH of membrane fusion was assayed by polykaryon
formation as detailed previously (Steinhauer et al.,
1991a). Briefly, BHK-21 cells were infected with recombi-
nant vaccinia viruses and at 15 h postinfection cells were
washed, trypsin-treated (5 mg/ml, 5 min, 37°C) to cleave
HA0 into HA1 and HA2, pH was adjusted for 1 min, then
neutralized, and cells were incubated in complete me-
dium for approximately 30 min. Cells were then fixed with
0.25% glutaraldehyde, stained with 1% toluidene blue,
and photographed.
Receptor binding
Receptor binding activity was assayed by binding of
red blood cells loaded with horseradish peroxidase
(HRP) to HA-expressing HeLa cell monolayers. Human
erythrocytes were loaded with HRP by the osmotic pre-
swelling method (Rechsteiner, 1982) and un-entrapped
HRP was removed by extensive washing. Recombinant
vaccinia virus-infected HA-expressing cells in 24-well
plates were treated with C. perfringens neuraminidase, a
procedure required to maximize the HA binding potential
(Ohuchi et al., 1995) and cells were trypsin-treated to
cleave HA0 into HA1 and HA2. HRP-loaded erythrocytes
(1% hematocrit) were then added and allowed to bind for
40 min at 37°C. Unbound red blood cells were removed
by extensive washing and cell monolayers were fixed
with 0.25% glutaraldehyde. The binding was quantified
by assaying for HRP using 3,39,5,59-tetramethylbenzi-
dene as substrate. The level of HA expression was
assessed by ELISA in identical wells using anti-HA rab-
bit polyclonal serum and protein A–HRP conjugate and
results were corrected for level of HA expression. As
negative controls we used vaccinia-infected cells not
expressing HA or erythrocytes which had been treated
with neuraminidase to remove receptors for HA. In the
horse serum inhibition assays, cells were incubated for 5
min prior to the addition of erythrocytes and serum and
erythrocytes were co-incubated with cells as described
above.
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